Cancer combo trial pulled before it even started
NCT ID NCT06152523
First seen Apr 08, 2026 · Last updated Jun 09, 2026 · Updated 10 times
Summary
This study was designed to test a combination of two immunotherapy drugs (monalizumab and MEDI5752) in people with MSI or dMMR metastatic cancers, which are types of tumors that often respond well to immunotherapy. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to see if the drug combination could shrink tumors and be safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of medical oncology - Saint-Antoine Hospital
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.